-
-
7 . Periodical
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or METamplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
- 저자
- by Wu, Yi-Long; Cheng, Ying; Zhou, Jianying; Lu, Shun; Zhang, Yiping, et al.
- 소스
- The Lancet Respiratory Medicine; November 2020, Vol. 8 Issue: 11 p1132-1143, 12p